Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 241 participants.
Also called NCT03434119
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 241 participants
- Sponsor
- Registry
-
NCT03434119
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Terminated
Technical summary
Registry record NCT03434119. Randomized; no masking; primary purpose treatment. Start 2018-02-20 (actual); primary completion 2019-01-07 (actual). Results posted on 2020-01-13.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents
- Acronym
- LixiLan-D
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Insulin glargine/Lixisenatide
- Intervention (Drug)
- Insulin glargine (HOE901)
- Intervention (Drug)
- Background therapy
- Lead sponsor
- Sanofi
Record details
- Record id
cardio:ct-nct03434119- Content hash
efb0a0793dc4db9d1c28cd168c9b8c25f8aa7b4fc15495846d1df2220139b422